It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Succinate dehydrogenase, which is known as mitochondrial complex II, has proven to be a fascinating machinery, attracting renewed and increased interest in its involvement in human diseases. Herein, we find that succinate dehydrogenase assembly factor 4 (SDHAF4) is downregulated in cardiac muscle in response to pathological stresses and in diseased hearts from human patients. Cardiac loss of Sdhaf4 suppresses complex II assembly and results in subunit degradation and complex II deficiency in fetal mice. These defects are exacerbated in young adults with globally impaired metabolic capacity and activation of dynamin-related protein 1, which induces excess mitochondrial fission and mitophagy, thereby causing progressive dilated cardiomyopathy and lethal heart failure in animals. Targeting mitochondria via supplementation with fumarate or inhibiting mitochondrial fission improves mitochondrial dynamics, partially restores cardiac function and prolongs the lifespan of mutant mice. Moreover, the addition of fumarate is found to dramatically improve cardiac function in myocardial infarction mice. These findings reveal a vital role for complex II assembly in the development of dilated cardiomyopathy and provide additional insights into therapeutic interventions for heart diseases.
Functional succinate dehydrogenase (SDH) complex is vital to mitochondrial homeostasis. Here the authors show that disruption of SDH assembly in the heart causes dilated cardiomyopathy via impairing the mitochondrial integrity and metabolism and that mitochondrial interventions can be an effective approach to ameliorate the disease progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Health and Rehabilitation Sciences, School of Health and Life Sciences, Qingdao, China; Xi’an Jiaotong University, Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
2 Fourth Military Medical University, Key Laboratory of Aerospace Medicine of the Ministry of Education, School of Aerospace Medicine, Xi’an, China (GRID:grid.233520.5) (ISNI:0000 0004 1761 4404)
3 Xi’an Jiaotong University, Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
4 Zhejiang University School of Medicine, Department of Cardiology, Provincial Key Lab of Cardiovascular Research, Second Affiliated Hospital, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, School of Medicine, Institute of Translational Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
5 The Second Affiliated Hospital of Xi’an Jiaotong University, National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, Xi’an, China (GRID:grid.452672.0) (ISNI:0000 0004 1757 5804)
6 Xi’an Jiaotong University Health Science Center, Department of Pharmacology, School of Basic Medical Sciences, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
7 University of Health and Rehabilitation Sciences, School of Health and Life Sciences, Qingdao, China (GRID:grid.43169.39); Xi’an Jiaotong University, Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)
8 University of Health and Rehabilitation Sciences, School of Health and Life Sciences, Qingdao, China (GRID:grid.43169.39); Xi’an Jiaotong University, Frontier Institute of Science and Technology, Xi’an, China (GRID:grid.43169.39) (ISNI:0000 0001 0599 1243)